New Zealand markets closed
  • NZX 50

    12,348.00
    -149.10 (-1.19%)
     
  • NZD/USD

    0.6713
    -0.0047 (-0.70%)
     
  • NZD/EUR

    0.5911
    -0.0058 (-0.97%)
     
  • ALL ORDS

    7,490.10
    -178.80 (-2.33%)
     
  • ASX 200

    7,175.80
    -166.60 (-2.27%)
     
  • OIL

    86.29
    -0.61 (-0.70%)
     
  • GOLD

    1,836.10
    -6.50 (-0.35%)
     
  • NASDAQ

    14,438.40
    -408.06 (-2.75%)
     
  • FTSE

    7,494.13
    -90.88 (-1.20%)
     
  • Dow Jones

    34,265.37
    -450.02 (-1.30%)
     
  • DAX

    15,603.88
    -308.45 (-1.94%)
     
  • Hang Seng

    24,965.55
    +13.20 (+0.05%)
     
  • NIKKEI 225

    27,522.26
    -250.67 (-0.90%)
     
  • NZD/JPY

    76.2790
    -0.7870 (-1.02%)
     

The Zacks Analyst Blog Highlights: Tesla, Meta Platforms, Abbott Lab, Comcast and 3M

·4-min read

For Immediate Release

Chicago, IL – December 3, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tesla, Inc. TSLA, Meta Platforms, Inc. FB, Abbott Laboratories ABT, Comcast Corporation CMCSA and 3M Company MMM.

Here are highlights from Thursday’s Analyst Blog:

Top Analyst Reports for Tesla, Meta Platforms and Abbott Labs

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Meta Platforms and Abbott Laboratories. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Tesla have outperformed the Zacks Domestic Automotive industry over the past year (+84.5% vs. +40.1%). The Zacks analyst believes that robust demand for Models 3 and Y has been buoying Tesla's revenues. Tesla achieved record production levels in the third quarter despite a chip crunch, on the back of robust demand for Model 3/Y cars.

With China being the biggest EV market, TSLA is poised to witness strong revenues from its Shanghai factory in the quarters ahead. Production from Berlin and Texas gigafactories is also expected to commence this year. In addition to increasing automotive revenues, Tesla’s energy generation and storage revenues are also boosting earnings prospects.

(You can read the full research report on Tesla here >>>)

Meta Platforms shares have gained +14.7% in the year-to-date period against the S&P 500’s gain of +22.7%. The Zacks analyst, however, believes that Meta has been benefiting from steady user growth across all regions, particularly Asia-Pacific. Increased engagement for its products like Instagram, WhatsApp, Messenger and Meta Watch has been a major growth driver.

FB’s focus on becoming a Metaverse company is noteworthy. Meta’s strong balance sheet and cash flow generating ability is a key catalyst. The tech giant, however, expects revenues to hurt from changes made by Apple in its iOS 14 update that limit its ability to track user-activity trends.

(You can read the full research report on Meta Platforms here >>>)

Shares of Abbott Laboratories have gained +19.7% in the last six months against the Zacks Medical Products industry’s gain of +8.5%. The Zacks analyst believes that strength in ABT’s branded generics and international diabetes businesses should drive growth in the coming quarters. New product launches and acquisitions is likely to boost sales further.

Abbott posted better-than-expected earnings and revenue numbers for the third quarter of 2021. Barring Neuromodulation, the company registered organic sales growth across each of its operating segments. In Adult Nutrition, ABT reported robust global demand for Ensure and Glucerna. Slow growth in the nutrition business in China, however, continues to dampen the top-line growth.

(You can read the full research report on Abbott Laboratories here >>>)

Other noteworthy reports we are featuring today include Comcast and 3M.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

https://www.zacks.com                                          

 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Abbott Laboratories (ABT) : Free Stock Analysis Report
 
Comcast Corporation (CMCSA) : Free Stock Analysis Report
 
3M Company (MMM) : Free Stock Analysis Report
 
Tesla, Inc. (TSLA) : Free Stock Analysis Report
 
Meta Platforms, Inc. (FB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting